Targeting different types of small cell lung cancer with new treatments
Combining CDK7 and MUC1-C inhibition to target different subtypes of small cell lung cancer
This study is looking at new ways to treat small cell lung cancer by testing combinations of treatments that target specific proteins, and it’s for patients who want to explore innovative options to improve their chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11043435 on NIH RePORTER |
What this research studies
This research focuses on small cell lung cancer (SCLC), a highly aggressive form of lung cancer that often recurs after initial treatment. The study aims to explore new treatment strategies by combining inhibitors that target specific proteins involved in the cancer's growth and survival. By understanding the different subtypes of SCLC and their unique characteristics, the research seeks to develop more effective therapies that could improve patient outcomes. Patients may have the opportunity to participate in trials that test these innovative treatment approaches.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with small cell lung cancer, particularly those whose disease has not responded well to standard treatments.
Not a fit: Patients with non-small cell lung cancer or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for small cell lung cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in targeting specific pathways in small cell lung cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Wong, Kwok Kin — New York University School of Medicine
- Study coordinator: Wong, Kwok Kin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.